Calmidazolium chloride (R 24571) is a calmodulin antagonist that antagonizes CaM-dependent phosphodiesterase and calmodulin-induced activation of Ca2+-transporting ATPase in erythrocytes with IC50s of 0.15 and 0.35 μM, respectively. it is also used in anticancer studies. It binds CaMK with a Kd value of 3 nM.
RLX-33 is a potent and selective blood-brain barrier permeable relaxin family peptide 3 (RXFP3) antagonist that also blocks relaxin 3 (Relaxin 3) -induced ERK1/2 phosphorylation. The IC50 phosphorylated RXFP3, ERK1 and ERK2 were 2.36μM, 7.82μM and 13.86μM, respectively. RLX-33 can block the increase of food intake in rats induced by RXFP3 selective...
RLX-33 is a potent and selective blood-brain barrier permeable relaxin family peptide 3 (RXFP3) antagonist that also blocks relaxin 3 (Relaxin 3) -induced ERK1/2 phosphorylation. The IC50 phosphorylated RXFP3, ERK1 and ERK2 were 2.36μM, 7.82μM and 13.86μM, respectively. RLX-33 can block the increase of food intake in rats induced by RXFP3 selective...
Balovaptan (RG7314) is an orally available, selective brain-penetrant vasopressin 1a (hV1a) receptor antagonist, with Kis of 1 and 39 nM for human (hV1a) and mouse (mV1a) receptors.
Balovaptan (RG7314) is an orally available, selective brain-penetrant vasopressin 1a (hV1a) receptor antagonist, with Kis of 1 and 39 nM for human (hV1a) and mouse (mV1a) receptors.
C12-200 is a benchmark ionizable cationic lipidoid along with helper lipids. C12-200 is commonly used for mRNA delivery.
CKK-E12 is a ionizable lipid in combination with other lipids make up the lipid nanoparticles which are used to deliver RNA-based therapeutics. CKK-E12 was highly selective toward liver parenchymal cell in vivo.
C12-200 is a benchmark ionizable cationic lipidoid along with helper lipids. C12-200 is commonly used for mRNA delivery.
C12-200 is a benchmark ionizable cationic lipidoid along with helper lipids. C12-200 is commonly used for mRNA delivery.
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist.
Rheb inhibitor NR1 is a Rheb inhibitor with an IC50 of 2.1 µM in the Rheb-IVK assay. Rheb inhibitor NR1 can directly bind Rheb in the switch II domain and selectively inhibit the activation of mechanistic target of rapamycin complex 1 (mTORC1). Rheb inhibitor NR1 does not influence mTORC2 activity.
HG106 is a potent SLC7A11 inhibitor, it can enhance ROS generation, ER stress, and lead to ultimately growth arrest specifically in KRAS-mutant lung adenocarcinoma (LUAD).